Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Cancer Nanomedicine Market Outlook 2022: 124 Clinical Drug Pipelines with 8 Marketed Cancer Nanomedicine Drugs - Research and Markets

This image opens in the lightbox

News provided by

Research and Markets

15 Feb, 2017, 22:10 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Feb. 15, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Cancer Nanomedicine Market Outlook 2022" report to their offering.

The future of cancer nanotechnology lies on a multifunctional nanoplatform that combines both therapeutic components and multimodality imaging. The ultimate goal is that multifunctional nanomedicine works as efficient, targeted in vivo drug delivery without systemic toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured noninvasively with time. In the future, nanotechnology could possibly be strategically implemented in new developing drug delivery systems which could lead to significant expansion in the drug markets.

These new drug delivery methods are likely to provide the appropriate platform for the pharmaceutical companies to reformulate their existing drugs in the market. This would in turn lead to extending the life of their products and ensuring an improved performance of drugs by increasing effectiveness, safety and patient adherence, and ultimately reducing healthcare costs.

Global Cancer Nanomedicine Market Outlook 2022 Report Highlights:

- Overview & Mechanism of Action of Nanomedicine

- Nanomedicine Engineering: Design & Strategy

- Cancer Nanomedicine as Diagnostic & Therapeutics Tool

- Global Cancer Nanomedicine Market Overview & Dynamics

- Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase

- Global Cancer Nanomedicine Clinical Pipeline: 124 Drug

- Marketed Cancer Nanomedicine: 8 Drugs

Key Topics Covered:

1. Cancer Nanomedicine: An Optimistic Avenue

1.1 Introduction

1.2 Emergence of Nanomedicines

2. Prerequisite of Nanomedicines

2.1 Conventional Cancer Treating Approaches

2.2 Nanomedicines: Overcoming the Hurdles

3. Diversification of Nanomedicines

3.1 Classification on Basis of Constituents

3.1.1 Inorganic Nanoparticles

3.1.2 Organic Nanoparticles

3.2 Classification on Basis of Applicability

3.2.1 Nanomedicine as Diagnostic Agents

3.2.2 Nanomedicine as Therapeutic Agents

3.2.3 Nanomedicine as Drug Delivery Agents

3.3 Classification on Basis of Dimensions

4. Mechanism of Action of Nanomedicine

4.1 Targeting Tumor Cells

4.1.1 Passive Targeting

4.1.2 Active Targeting

4.2 Nanocarrier - Drug Complex

4.2.1 Liposomes

4.2.2 Dendrimers

4.2.3 Micelles

4.2.4 Inorganic Nanocarriers

4.3 Drug Release Systems

5. Nanomedicine Engineering: Design & Strategy

5.1 Organic Nanoparticles as Nanomedicines

5.1.1 Polymeric Nanoparticle

5.1.2 Lipid Organic Nanoparticles

5.2 Inorganic Nanoparticles as Nanomedicines

5.2.1 Synthesis of Gold Nanoparticle

6. Cancer Nanomedicine as Diagnostic Tool

6.1 Detection of Cancer Biomarkers

6.1.1 Detection of Circulating Tumor Cell

6.2 Diagnostic Device & Nanoprobes

6.2.1 Biosensors

6.2.2 Microarrays

6.3 Quantum Dots for Early Cancer Detection

6.3.1 Detection of primary Cancers

6.3.2 Quantum Dots for Tumor Imaging

7. Cancer Therapeutics with Nanomedicines

7.1 Nanomedicine as Therapeutic Agents

7.1.1 Photodynamic Therapy

7.1.2 Photo Thermal Therapy

7.2 Nanomedicines as Prophylactic & Therapeutic Approach

7.2.1 Cancer Cell Destruction

7.3 Nanomedicine in Breast Cancer

7.4 Nanomedicine in Pancreatic Cancer

7.5 Nanomedicine in Brain Cancer

7.6 Nanomedicine in Lung Cancer

8. Cancer Imaging with Nanomedicine

8.1 Positron Emission Tomography

8.1.1 Applications in various Cancers

8.2 Single Photon Emitted Tomography

8.2.1 Computed Tomography

8.3 Magnetic Resonance Imaging (MRI)

8.3.1 Optical Imaging

9. Drug Delivery with Nanomedicines

9.1 Nanocarrier & Chemotherapy

9.1.1 Peptide Nanomedicine- An Example of Nanocarrier Chemotherapy

9.2 Nanomedicine Endocytosis & Intracellular Mechanisms

9.3 Factors Affecting Drug Delivery

10. Global Cancer Nanomedicine Market Overview

10.1 Current Market Scenario

10.2 Global Cancer Nanomedicine Clinical Pipeline Overview

11. Global Nanomedicine Market Dynamics

11.1 Encouraging Market Aspects

11.2 Commercialization Challenges

12. Global Cancer Nanomedicine Future Prospect

13. Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase

13.1 Research

13.2 Preclinical

13.3 Phase-I

13.4 Phase-I/II

13.5 Phase-II

13.6 Phase-III

14. Marketed Cancer Nanomedicine Clinical Insight by Company, Indication & Phase

14.1 Doxorubicin Liposomal (Caelyx & Doxil)

14.2 Albumin-Bound Paclitaxel (Abraxane & Coraxane)

14.3 Nilotinib (Tasigna)

14.4 Paclitaxel Polymeric Micelle Formulation (Cynviloq & Genexol-PM)

14.5 Paclitaxel Liposomal

14.6 Vincristine Liposomal (Marqibo)

14.7 Rexin-G

14.8 Paclitaxel Nanoparticle (Nanoxel)

15. Competitive Landscape

15.1 Abraxis BioScience

15.2 Access Pharmaceuticals

15.3 Alnylam Pharmaceuticals

15.4 Amgen

15.5 Arrowhead Research

15.6 BIND Therapeutics

15.7 Cadila Healthcare

15.8 Celegen Corporation

15.9 Celsion Corporation

15.10 Genzyme Corporation

15.11 Merck

15.12 NanoCarrier

15.13 Nippon Kayaku

15.14 Nanobiotix

15.15 Novavax

15.16 Pfizer

15.17 Roche

15.18 Samyang

15.19 Sanofi

15.20 Takeda Pharmaceutical

For more information about this report visit http://www.researchandmarkets.com/research/8q3fcs/global_cancer

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.